These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Plesnicar BK; Zalar B; Breskvar K; Dolzan V J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753 [TBL] [Abstract][Full Text] [Related]
7. Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. Zastrozhin MS; Efimova AV; Skryabin V; Smirnov VV; Petukhov AE; Pankratenko EP; Pozdniakov SA; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA Psychopharmacol Bull; 2021 Nov; 51(4):87-104. PubMed ID: 34887601 [TBL] [Abstract][Full Text] [Related]
8. Investigating the Use of Pharmacogenetic and Pharmacometabolomic Markers to Predict Haloperidol Efficacy and Safety Rates. Skryabin VY; Zastrozhin MS; Parkhomenko AA; Pankratenko EP; Pozdnyakov SA; Denisenko NP; Akmalova KA; Bryun EA; Sychev DA Hosp Pharm; 2023 Aug; 58(4):363-367. PubMed ID: 37360210 [No Abstract] [Full Text] [Related]
9. The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder. Zastrozhin ; Smirnov ; Petukhov ; Pankratenko ; Zastrozhina ; Grishina ; Ryzhikova ; Bure ; Skryabin ; Vlasovskih ; Bryun ; Sychev Psychopharmacol Bull; 2020 Jul; 50(3):58-75. PubMed ID: 32733112 [TBL] [Abstract][Full Text] [Related]
10. Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder. Zastrozhin ; Petukhov ; Pankratenko ; Grishina ; Ryzhikova ; Skryabin ; Koporov ; Bryun ; Sychev Psychopharmacol Bull; 2020 Jul; 50(3):47-57. PubMed ID: 32733111 [TBL] [Abstract][Full Text] [Related]
11. Genetic Testing is Superior Over Endogenous Pharmacometabolomic Markers to Predict Safety of Haloperidol in Patients with Alcohol-induced Psychotic Disorder. Skryabin V; Zastrozhin M; Parkhomenko A; Lauschke VM; Smirnov V; Petukhov A; Pankratenko E; Pozdnyakov S; Koporov S; Denisenko N; Akmalova K; Bryun E; Sychev D Curr Drug Metab; 2022; 23(13):1067-1071. PubMed ID: 36579390 [TBL] [Abstract][Full Text] [Related]
13. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. Zastrozhin MS; Skryabin VY; Smirnov VV; Petukhov AE; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Bure IV; Golovinskii PA; Koporov SG; Bryun EA; Sychev DA Gene; 2020 May; 739():144513. PubMed ID: 32112986 [TBL] [Abstract][Full Text] [Related]
14. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141 [TBL] [Abstract][Full Text] [Related]
15. The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders. Kibitov AA; Kiryanova EM; Salnikova LI; Bure IV; Shmukler AB; Kibitov AO Drug Metab Pers Ther; 2023 Jun; 38(2):133-142. PubMed ID: 36437548 [TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. Zastrozhin MS; Skryabin VY; Petukhov AE; Pankratenko EP; Grishina EA; Ryzhikova KA; Torrado MV; Shipitsyn VV; Bryun EA; Sychev DA J Psychiatr Pract; 2021 Sep; 27(5):372-379. PubMed ID: 34529603 [TBL] [Abstract][Full Text] [Related]
17. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646 [TBL] [Abstract][Full Text] [Related]
18. Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. Zastrozhin M; Skryabin V; Smirnov V; Zastrozhina A; Grishina E; Ryzhikova K; Bure I; Golovinskii P; Koporov S; Bryun E; Sychev D Am J Ther; 2021 Jun; 29(1):e26-e33. PubMed ID: 34117140 [TBL] [Abstract][Full Text] [Related]
19. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795 [TBL] [Abstract][Full Text] [Related]
20. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Zastrozhin MS; Skryabin VY; Smirnov VV; Grishina EA; Ryzhikova KA; Chumakov EM; Bryun EA; Sychev DA Can J Physiol Pharmacol; 2019 Aug; 97(8):781-785. PubMed ID: 31100205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]